September 7, 2005. On Thursday and Friday of this week, a special FDA panel will hold hearings on two new, and potentially huge, diabetes drugs: Exubera from Pfizer, Sanofi-Aventis and Nektar, wants to bring an inhaled form of insulin to market, and Pargluva, from Bristol-Myers Squibb and Merck, targets type 2 diabetes patients before they take insulin. Both are effective, but both have side effects. We take a look at the outlook...
